26-02-2001

Seh-26-01 12:09

- 75 -

## What is claimed is:

- A soluble proteic fragment of a subtilisin-kexin isoenzyme named SKI-1 which has the amino acid sequence defined by amino acids 187 to 996 of any one of SEQ ID NOs. 2, 4 and 6, and a variant thereof, which is enzymatically active.
- A proteic fragment of a subtilisin-kexin isoenzyme named SKI-1, which has the 5 amino acid sequence defined by amino acids 18 to 137 of any one of SEQ ID NOs: 2, 4 and 6, and a variant thereof, which is capable of binding with amino acids 18 to 1052 of SKI-1 in whole or in part.
- The proteic fragment of claim 2, wherein said part has a molecular weight of about 3. 14 KDa and forms a tight complex with the soluble fragment of SKI-1 as defined in 10 claim 1.
  - The proteic fragment of claim 2, which is an inhibitor of SKI-1 activity. 4.
- The proteic fragment of claim 4, wherein the SKI-1 amino acid sequence that is modified to prevent further enzymatic processing in a cell expressing said proteic 15 fragment.
  - The proteic fragment of claim 5, which is modified by amino acid substitution, 6. deletion or rearrangement.
  - An isolated nucleic acid endoding a protein fragment as defined in claim 1. 7.
  - An isolated nucleic acid encoding a proteic fragment as defined in claim 2. 8.
- An isolated nucleic acid encoding a proteic fragment as defined in claim 3. 20 9.
  - An isolated nucleic acid encoding a proteic fragment as defined in any one of 10. claims 4 to 6.
  - A recombinant vector comprising the nucleic acid defined in any one of claims 7 11. to 10.
- The recombinant vector of claim 11, which is an expression vector. 25 12.

10

15

25

26-02-2001

- 76 -

- The recombinant vector of claim 12, which comprises a promoter expressible in 13. a target cell wherein expression of said nucleic acid is desirable.
- The recombinant vector of claim 12, which comprises an inducible promoter. 14.
- A recombinant host cell comprising the recombinant vector defined in any one of 15. 5 claims 11 to 14.
  - A method of producing a proteic fragment of SKI-1 enzyme, which comprises the 16. steps of:

culturing a recombinant host cell expressing a nucleic acid as defined in any one of claims 7 to 10 in a cell growth and expression-supportive culture medium; and recovering said proteic fragment of SKI-1 in the culture medium.

- A method for cleaving a substrate for SKI-1 enzyme, which comprises the step of: 17.
- contacting said substrate with a SKI-1 enzyme which has 1) an amino a) acid sequence defined by amino acids 18 to 1052 of any one of SEQ ID Nos: 2, 4, 6 and an active variant thereof, or 2) a SKI-1 soluble fragment as defined in claim 1, or 3) a catalytic part of a) or b), or 4) a complex as defined in claim 3, for a time sufficient and in conditions adequate for such cleavage to occur,

with the proviso that said substrate is not a sterol-regulatory element-binding protein (SREBP).

- A method for producing a protein or a peptide from a proteic precursor which is an 18. enzymatic substrate for SKI-1 enzyme, which comprises the steps of: 20
  - contacting said proteic precursor with a SKI-1 enzyme which has 1) an a) amino acid sequence defined by amino acids 18 to 1052 of any one of SEQ ID Nos: 2, 4. 6 and an active variant thereof, or 2) a SKI-1 soluble fragment as defined in claim 1, or 3) a catalytic part of a) or b), or 4) a complex as defined in claim 3, for a time sufficient and in conditions adequate for such cleavage to occur; and
    - recovering said protein or peptide; b)

- 77 -

M. S. A. P. M. S. A. P. S. A.

5

10

**}**# []

ļ

to CJ

ķė

with the proviso that said substrate is not a sterol-regulatory element-binding protein (SREBP).

- The method of claim 17, which takes place in a cell or in the presence of a cellular 19. population and wherein step a) comprises the step of transfecting a cell with a nucleic acid expressing said SKI-1 enzyme.
- The method of claim 19, wherein said cell expresses said proteic precursor or is 20. transfected with a nucleic acid expressing said proteic precursor.
- A method of inhibiting the activity of a subtilisin-kexin isoenzyme named SKI-1, 21. which comprises the step of contacting SKI-1with the inhibitor defined in any one of claims 4 to 6, 8 and 10.
  - A peptide of at least 7 amino acids capable of binding to and of being cleaved by 22. SKI-1 catalytic site, comprising the following general formula:

Arg Xaa₁ J Xaa₂ ↓ Xaa₃ (Z)n O

wherein

Xaa<sub>1, 2, 3</sub> and Z are any amino acid

15

J is an alkyl or aromatic hydrophobic amino acid

n is 1, 2 or 3

O is an acidic amino acid,

with the proviso that the peptide does not comprise the sequence Lys - Arg - Phe - Val - Phe - Asn - Lys - lie - Glu.

- A peptide as defined in claim 22, wherein Xaa2 is Lys, Leu, Phe or Thr. 23. 20
  - A peptide as defined in claim 23 which has the sequence: 24.

H2N-Val-Phe-Arg-Ser-Leu-Lys-Tyr-Ala-Glu-Ser-Asp-COOH.

- A peptide as defined in any one of claims 22 to 24 which is labell d. 25.
- A peptide as defined in claim 25 which is fluorogenic. 26.

A COMPANY

27. A peptide as defined in claim 26 which is

Abz-Val-Phe-Arg-Ser-Leu-Lys-Tyr-Ala-Glu-Ser-Asp-Tyr(NO2),

wherein

Abz is orthoaminobenzoic acid, and

- 5 Tyr(NO<sub>2</sub>)is 3-nitrotyrosine.
  - 28. The use of a peptide as defined in any one of claims 22 to 27 for monitoring the activity of a subtilisin-kexin isoenzyme named SKI-1.
  - 29. The use as defined in any one of claims 22 to 27 for screening inhibitors of a subtilisin-kexin isoenzyme named SKI-1.
- 10 30. The use as defined in any one of claims 22 to 27 for screening a subtilisin-kexin isoenzyme named SKI-1.
  - 31. The use of a peptide of at least 7 amino acids capable of binding to and of being cleaved by SKI-1 catalytic site, comprising the following general formula:

Arg Xaa₁ J Xaa₂ ↓ Xaa₃ (Z)n O

15 wherein

CE

Xaa1, 2, 3 and Z are any amino acid

J is an alkyl or aromatic hydrophobic amino acid

n is 1, 2 or 3

O is an acidic amino acid

for monitoring the activity of a subtilisin-kexin isoenzyme named SKI-1.

21) 32. The use of a peptide of at least 7 amino acids capable of binding to and of being cleaved by SKI-1 catalytic site, comprising the following general formula:

Arg Xaa₁ J Xaa₂ ↓ Xaa₃ (Z)n O

wherein

Xaa1, 2, 3 and Z are any amino acid

÷

14



10

15

J is an alkyl or aromatic hydrophobic amino acid

n is 1, 2 or 3

## O is an acidic amino acid

for screening inhibitors or substrates of a subtilisin-kexin isoenzyme named SKI-1.

- 5 33. The use of an inhibitor of the activity of a subtilisin-kexin isoenzyme named SKI-1 in the making of a medication for treating a disease involving an overexpression of a SKI-1 or a SKI-1 substrate.
  - 34. The use as defined in claim 33, wherein said disease is associated with any one of hypercholesterolemia, high levels of fatty acids, lipids or farmesyl pyrophosphate, liver steatosis, Ras-dependent cancer, restenosis and amyloid protein formation.
    - 35. The use as defined in claim 33 or 34, wherein said inhibitor is defined in any one of claims 2, 4 to 6, 8 and 10.
  - 36. A composition comprising a SKI-1 fragment as defined in any one of claims 1 to 6, or a nucleic acid defined in any one of claims 7 to 10, or a recombinant vector as defined in any one of claims 7 to 10, or a recombinant vector as defined in any ne of claims 11 to 14.
- 37. The use of a SKI-1 enzyme as encoded by nucleic acids to 18 to 1052 of SEQ ID NOs: 1, 3 or 5, or of a catalytic part that is unique to SKI-1 enzyme, or of an active variant thereof, the nucleic acid of the variant sharing at least 70% homology with the nucleic defined in SEQ ID NOs.: 1, 3 and 5 and hybridizing therewith under stringent hybridization conditions, for cleaving a proteic precursor, with the proviso that said proteic precursor is not a sterol-regulatory element-binding protein (SREBP).